Sclerostin antibodies as novel anabolic therapy for osteoporosis
| Autor: | Elizaveta O. Mamedova, Tatiana A. Grebennikova, Zhanna E. Belaya, Liudmila Y. Rozhinskaya |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Остеопороз и остеопатии, Vol 21, Iss 3, Pp 21-29 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2072-2680 2311-0716 |
| DOI: | 10.14341/osteo10127 |
| Popis: | Osteoporosis medications are dividedinto two groups: those inhibiting bone resorption and formation (bisphosphonates and denosumab), and those stimulating bone formation i.e. having an anabolic effect. The latter include teriparatide, parathyroid hormone 1-84 and abaloparatide, all of which stimulate bone resorption as well as bone formation, which limits their anabolic effect. The discovery of sclerostin the key inhibitor of bone formation has led to development of the concept that inhibition of this protein could stimulate bone formation. Romosozumab is a human monoclonal antibody to sclerostin that binds to sclerostin and enables Wnt-signaling pathway ligands and their co-receptors to interact with each other, which, in turn, leads to increased bone formation and bone mineral density. Unlike classical anabolic drugs in osteoporosis treatment, romosozumab stimulates bone formation and inhibits bone resorption. In clinical trials, romosozumab showed marked increase in lumbar spine and hip bone mineral density. Presented article contains information about pre-clinical and clinical studies of romosozumab. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|